Simpson Thacher represented J.P. Morgan Securities plc, as sole bookrunner and sole lead manager, in connection with the offering of US$300 million 2.75% Convertible Bonds due 2018 by Celltrion, Inc. The offering was conducted in reliance upon Regulation S under the Securities Act of 1933, as amended.
Celltrion is a leading biopharmaceutical company based in Korea specializing in the research, development and manufacture of biosimilar and other biological products. The common shares of Celltrion are traded on the KRX KOSDAQ Market in Korea under the trading code 068270. The Convertible Bonds are listed on the Singapore Stock Exchange.
The Simpson Thacher team for the transaction included Youngjin Sohn and Iksoo Kim (Corporate – Seoul) and Kristina Kang and Sebyul Chun (Corporate – Hong Kong).
